MITOKININ
Mitokinin is operates in the healthcare industry focusing on biotechnology business. It launches medicinal chemistry effort to generate kinetin analogs optimized for activating PINK1. It plans to develop the analog or optimized variants to treat Parkinson's disease.
MITOKININ
Industry:
Biotechnology Health Care Life Science
Founded:
2017-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.mitokinin.com
Total Employee:
11+
Status:
Active
Contact:
(347) 668-8061
Total Funding:
5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt WordPress Wordpress Plugins Nginx Sitelinks Search Box Euro
Similar Organizations
BALX Holdings
Balx Holdings operates in the healthcare industry focusing on biotechnology business.
Centrexion
Centrexion operates in the healthcare industry, focusing on the biotechnology business.
Kytopen
Kytopen developer of a cell therapy platform for non-viral delivery of molecules into hard-to-transfect immune cells.
Orionis Biosciences
Orionis Biosciences operates in the healthcare industry focusing on biotechnology business & innovation.
Patara Pharma
Patara Pharma operates in the healthcare industry focusing on the biotechnology business.
Rocket Pharmaceuticals
Rocket Pharmaceuticals Ltd. operates in the healthcare industry focusing on biotechnology business.
Sidero Bioscience
Sidero Bioscience operates in the healthcare industry focusing on biotechnology business.
Symic Biomedical
SYMIC Biomedical operates in the healthcare industry focusing on biotechnology business.
Tetherex Pharmaceuticals
Tetherex Pharmaceuticals operates in the healthcare industry focusing on biotechnology business.
Vetica Labs
Vetica Labs is operates in the healthcare industry focusing on biotechnology business.
Current Employees Featured
Founder
Investors List
Mission BioCapital
Mission BioCapital investment in Series A - Mitokinin
Official Site Inspections
http://www.mitokinin.com
- Host name: 159.180.132.176
- IP address: 159.180.132.176
- Location: North Chicago United States
- Latitude: 42.325
- Longitude: -87.8561
- Metro Code: 602
- Timezone: America/Chicago
- Postal: 60064
More informations about "Mitokinin"
Mitokinin is now part of AbbVie | AbbVie
We’re delivering science that takes us closer to meaningful change for people with neurological and psychiatric disorders. As one company, our ~50,000 employees around the world focus …See details»
AbbVie Exercises Exclusive Right to Acquire Mitokinin, Further ...
Oct 5, 2023 · - Mitokinin's lead compound, a selective PINK1 activator, is designed to address mitochondrial dysfunction, which plays a key role in the pathogenesis of Parkinson's disease. - …See details»
AbbVie acquires Parkinson’s drug in latest biotech buyout
Oct 5, 2023 · Mitokinin says its drugs are designed to increase PINK1 activity and thereby help patients with Parkinson’s. AbbVie has now exercised an exclusive right to acquire Mitokinin …See details»
AbbVie Exercises Exclusive Right to Acquire Mitokinin, Further ...
Oct 5, 2023 · - Mitokinin's lead compound, a selective PINK1 activator, is designed to address mitochondrial dysfunction, which plays a key role in the pathogenesis of Parkinson's disease. - …See details»
Mitokinin, Inc., Enters into Purchase Right Agreement with AbbVie
Mar 2, 2021 · Mitokinin is a discovery-stage biotechnology company developing PINK1 targeted therapeutics for the treatment of neurodegenerative and mitochondrial diseases. Mitokinin’s …See details»
Mitokinin - Crunchbase Company Profile & Funding
Mitokinin is operates in the healthcare industry focusing on biotechnology business. It launches medicinal chemistry effort to generate kinetin analogs optimized for activating PINK1. It plans …See details»
AbbVie Exercises Exclusive Right to Acquire Mitokinin
Nov 14, 2023 · The foundational technology developed by UCSF inventors activates PINK1 to remediate mitochondrial damage, a key driver in the pathogenesis of Parkinson’s disease. …See details»
Mitokinin, Inc., Enters into Purchase Right Agreement with AbbVie
Mar 2, 2021 · Mitokinin is a discovery-stage biotechnology company developing PINK1 targeted therapeutics for the treatment of neurodegenerative and mitochondrial diseases. Mitokinin’s …See details»
Mitokinin, Inc., Enters into Purchase Right Agreement with AbbVie
Mar 2, 2021 · Mitokinin is a discovery-stage biotechnology company developing PINK1 targeted therapeutics for the treatment of neurodegenerative and mitochondrial diseases. Mitokinin's …See details»
AbbVie to Acquire Mitokinin, Strengthening Neuroscience Pipeline
Oct 5, 2023 · AbbVie announced that it has exercised its exclusive right and completed the acquisition of Mitokinin, a discovery-stage biotechnology company developing a potentially first …See details»
AbbVie Exercises Exclusive Right to Acquire Mitokinin
Oct 6, 2023 · AbbVie announced today that it has exercised its exclusive right and completed the acquisition of Mitokinin, a discovery-stage biotechnology company developing a potentially first …See details»
AbbVie gets rights to acquire Parkinson’s disease start-up Mitokinin
Mar 5, 2021 · AbbVie is collaborating with the start-up Mitokinin on an early-stage small molecule for Parkinson’s disease. The compound targets the kinase PINK1 to increase its activity and …See details»
AbbVie completes Mitokinin acquisition worth $110M - Pharma …
Oct 6, 2023 · AbbVie has completed its acquisition of Mitokinin, a biotech focused on developing a novel treatment for Parkinson's disease, the drugmaker announced this week.See details»
Mitokinin - MitoWorld
Mitokinin has combined a genetically validated target, a class of potent, highly selective small molecules, and a world-class scientific team to tackle the most critical unmet medical need of …See details»
AbbVie, Mitokinin Partner to Advance PINK1 Program
Mar 4, 2021 · Mitokinin’s lead clinical program is focused on PINK1-targeted therapeutics for both neurodegenerative and mitochondrial diseases. Specifically, it targets idiopathic Parkinson’s …See details»
Mitokinin - Org Chart, Teams, Culture & Jobs - The Org
View Mitokinin's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Mitokinin Company Profile - Office Locations, Competitors, …
Mitokinin is a company that delivers drugs addressing neurodegenerative diseases. It focuses on small molecule therapeutics that specifically increase the activity of active-form PINK1.See details»
“De-Risking” Success Stories: Paving the Way for Groundbreaking ...
Dec 21, 2023 · Mitokinin: A Game-Changer in Mitochondrial Dysfunction . Since 2009, MJFF has supported a company called Mitokinin with research grants. These grants empowered the …See details»
Nicholas Hertz - Co-founder & CSO at Mitokinin - The Org
Dr. Hertz’s graduate research with Kevan Shokat provided the foundation for Mitokinin’s PINK1 program. Dr. Hertz leads a team of 12 scientists and research associates, along with 8 FTEs …See details»